Megan Molteni, Wired, 26 January 2018, https://www.wired.com/story/what-good-is-crispr-if-it-cant-get-where-it-needs-to-go/
Many different research groups and companies are working on the creation of CRISPR-based gene therapies. However, delivery of these therapies remains a significant obstacle. Traditionally, gene therapies have been packaged in Adeno-associated viruses, but the size of the CRISPR machinery prevents this method of delivery. To solve these problems, researchers are working on novel delivery mechanisms, including the use of gold nanoparticles. Notably, a UC-Berkeley spin-off company has been created to focus solely on delivery of the CRISPR/Cas machinery.